Risks of testosterone for postmenopausal women

• Autores: JoAnn V. Pinkerton, Isabella Blackman, Edward Alexander Conner, Andrew M. Kaunitz
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 50, Nº. 1, 2021 (Ejemplar dedicado a: Androgens in Women: Too Much, Too Little, Just Right), págs. 139-150
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Transdermal testosterone therapy, dosed within premenopausal physiologic testosterone ranges, used alone or with menopausal hormone therapy for postmenopausal hypoactive sexual desire disorder, has shown short-term efficacy, with few androgenic side effects. After natural or surgical menopause, meaningful improvements include an additional satisfying sexual episode per month; improvement in desire, arousal, orgasm, pleasure, and responsiveness; and a reduction in distress. Long-term data on cardiovascular, cancer, and cognitive safety are lacking. No approved testosterone preparation is available for women. Compounded testosterone creams or reduced dosing of male-approved therapies represent off-label use. Injections or pellets cause supraphysiological testosterone levels and are not recommended.